Deys Medical Stores (Mfg) Limited Unlisted Shares Annual Reports

Deys Medical Stores (Mfg) Limited Unlisted Shares

The document is the standalone financial statements of Dey's Medical Stores (Manufacturing) Ltd for the period 01/04/2020 to 31/03/2021. The statements are presented in thousands of INR unless otherwise specified. **General Information about Company** * Name: Dey's Medical Stores (Manufacturing) Ltd * Corporate Identity Number: U24232WB1957PLC023528 * Permanent Account Number: AABCD1608D * Address: 62 Bondel Road, Kolkata, West Bengal, 700019, INDIA * Industry: Commercial, Industrial and Pharmaceutical Products * Category: Public Company Limited by Shares, Indian Non-Government Company * Listed Company: No * Number of Employees: 829 * Sustainability Report: No * Date of Final Accounts Approval: 25/08/2021 * Reporting Period: 12 Months (01/04/2020 - 31/03/2021) * Report Nature: Standalone Financial Statements * Presentation Currency: INR * Level of Rounding: Thousands * Cash Flow Statement Type: Indirect Method * Registrar and Transfer Agent: Maheshwari Datamatics Pvt. Ltd., 23 N. Mukherjee Road, Kolkata 700001, e-mail mdpldc@yahoo.com, Phone: 033-22482248, 2243-5029 * Electronic Records: Yes * Number of Product/Service Categories: 1 * Principal Product/Services: Pharmaceutical Products * Principal Product/Service Category (ITC 4 digit) Code: 3004, Description: ITONE EYE DROP MOM PLUS, Turnover: 2,63,817 **Directors' Report Disclosures** * Directors Signing Board Report: Gautam Dey (Managing Director, DIN: 01277238) and Ranajit Dey (Wholetime Director, DIN: 01277323), signed on 25/08/2021. * Principal Business Activities contributing 10% or more of total turnover: NA. **Directors' Responsibility Statement** The directors confirm that: * Applicable accounting standards have been followed with no material departures. * Accounting policies are consistently applied, and judgments/estimates are reasonable. * Sufficient care has been taken for the maintenance of adequate accounting records. * Annual accounts are prepared on a going concern basis. * Proper systems are in place to ensure compliance with applicable laws. **Directors and Key Managerial Personnel** * Bhaskar Ghose (DIN - 00007714) and Debashis Mazumdar (DIN - 00119396) are retiring by rotation and offer themselves for reappointment. * Dr. Bhaskar Banerjee (DIN - 00603201) was appointed as an Additional Director. * Subharthee Dey (DIN - 01277345) passed away on 11th October 2020. **Independent Directors** * Dr. Amit Kumar Roy (DIN - 06910710) and Mr. Dwarakeswar Chatterjee (DIN - 08390801) are the independent directors. **Meetings of the Board** The board met four times during the year on 03.08.2020, 05.11.2020, 14.12.2020 and 24.03.2021. **Auditors** * M/s. Nundy, Roy & Co. are the auditors. **Deposits** * The Company has not accepted any deposits covered under Chapter V of Companies Act 2013 **Related Party Transactions** * Contracts and arrangements with Day's Medical Stores Private Limited (DMSPL) and Dey*s Medical (U.P.) Private Limited [DM(UP)PL] were approved by the board as transactions in ordinary course of business on the same footing as if such transactions were entered with unrelated parties on arm's length basis. **Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo** * Details are given in Annexure-A. **Audit Committee** * The audit committee consists of Mr. Dwarakeswar Chatterjee (Chairman) and Dr. Amit Kumar Roy (Member). **Nomination and Remuneration Committee** * The committee has formulated a Nomination and Remuneration Policy. **Corporate Social Responsibility** * The CSR Committee comprises Gautam Dey, Ranajit Dey, and Dr. Amit Kumar Roy. * CSR Policy is available on the website. **Investor Education and Protection Fund (IEPF)** * 88 equity shares were transferred to IEPF. **Internal Financial Controls** * Adequate internal financial controls are in place. **Risk Management** * A Risk Management Policy is in place. **Significant and Material Orders** * There are no significant and material orders passed by any Regulators/Courts. **Performance and Financial Position of Subsidiaries, Associates and Joint Venture Companies** * The Company does not have any Subsidiary, Joint Venture Company and/or Associate Company. **Loans, Investments and Guarantee** * The Company did not give any loans or make any investment or provide any security **Remuneration received by Directors from Holding Company** * Gautam Dey: Rs. 68,60,462.00 * Ranajit Dey: Rs. 63,19,257.00 * Subharthee Dey: Rs. 42,86,097.00 **Sexual Harassment** * No complaints were received or disposed of during the financial year. **Industrial Relations** * Industrial relations remained cordial. **Disclosure** * The Directors have devised proper systems and procedures for ensuring compliance with all applicable secretarial standards. **Acknowledgment** * The directors acknowledged the cooperation and support of various government departments, banks, and industry associations. **A. CONSERVATION OF ENERGY:** **Steps taken on conservation of energy:** 1) Focus and emphasis on continued reduction of energy costs. 2) Installation of star rated motors in different applications to reduce energy consumption. 3) Upgrading & implementing the additional capacitor banks od 25KVAR for all Capacitor control panels, so that, we can archive good power factor. 4) Continuing the replacement of Prefilter, Hepa Filter and other filters in different intervals. 5) Implemented the variable frequency drives in different process applications. 6) Continuing replacement of old ducts with new duct (22/24 gauge) with best quality of insulation material with self-adhesive type Arm flex class O instead of traditional. 7) Continuing the use of dosing chemicals for the Boiler & Cooling towers. 8) Implementation of LED fixtures for all new projects. **(b) IMPROVEMENTS:** - With the use of energy Star rated motors with high efficiency which leads to 10-15% saving of power. - With proper maintenance & periodic checking of all capacitor panels which leads to get the monthly P.F. rebate from the electricity bill, Average saving per Month from CESC Bill - Rs 30,000/- approx.. (On Actual). - By periodic replacement of all filters with necessary automation, so that run time of AC compressor can be minimized which leads to further power saving of 10-15%. - With the help of preventive maintenance / cleaning of boiler with proper dosing of chemicals which helps to reduce consumption of furnace oil (FY 2020-2021 - Saving of 1184 lts from last financial year) - On Actual **IMPACT OF (a) AND (b):** *With earlier and current effect of (a) & (b) will enhance operational efficiency of the Company now and also in future. **B. TECHNOLOGY, ABSORPTION, ADOPTION & INNOVATION:** 1. **EFFORTS MADE:** * (a) To prepare a new formulation for ImmunoXI Capsules. * (b) To prepare a new formulation for Prostina Capsule. * (c) Therapeutic efficacy of Ursodeoxycholic Acid (Fortibile o?= tablet) on Nonsteroidal Antiinflamatory Drug (NSID) - included Hepatic Dysfunction in Experimental Animals. * (d) Mitigating effort of herbal medicine - Livina o?= upon serum, liver and kidney against ethanol induced oxidative strees in mice. * (e) Preliminary single dose toxicological investigation of Livina Capsule in mice model. 2. **NEW PROCESS DEVELOPED:** * (a) New process developed for Itone Eye Drops. * (b) New process developed for Enteromycetin Suspension. * (c) New process developed for Karpin Lotion. * (d) RP-HPLC method development & validation of Moxifloxacin Hydrochloride. 3. **IMPROVEMENT IN THE PRODUCT & PROCESS:** * (a) Improvement in the product and process of Enteromycetin Caplets-500. * (b) Improvement in the product and process of Hexide. * (c) Improvement in the product and process of Neo Kim Vet. * (d) Estimation of Isopropyl Alcohol with HPCL using Refractive Index Detector. 4. **BENEFITS:** * A few of the above products have already been placed in the market. Other products will be in the market soon. 5. **EXPENDITURE ON R & D:** (Rs. in Lakhs) * Capital Expenditure 10.77 * Recurring (including Market Research & Development) 154.35 * Total Expenses 165.12 * Total as % of Revenue from Operations 1.50 **FOREIGN EXCHANGE EARNINGS AND OUTGO:** (Rs. in Lakhs) (i) Foreign Exchange Export Sales (FOB) NIL (ii) Foreign Exchange Outgo (including raw 386.25 materials, spare parts, Capital Goods and other Expenditure in foreign currency). **FORMAT FOR THE ANNUAL REPORT ON CSR ACTIVITIES** The Company is committed to operate its business in an economically, socially and environmentally sustainable manner, while recognizing the interest of all its stakeholders. The whole direction is to generate community goodwill for the Company and socially responsible image as a good corporate citizen of the country. The CSR Committee of the Board comprise (a) Mr. Gautam Day, Managing Director, (b) Mr. Ranajit Dey, Joint Managing Director, (c) Dr. Amit Kumar Roy, Independent Director. Mr. Gautam Dey is the Chairman of the Committee. All the members of the Committee were present at the CSR Committee meeting held on 16thNovember, 2020. Total Amount Spent for the Financial Year (in Rs.) 2020-2021 NIL Amount transferred to any fund specified under Schedule VII as per second proviso to Section 135(5) Rs.15,25,673. **Financial Results (As at 31.03.2021):** * Revenue from Operations: 110,11,07 * Profit before Depreciation: 15,22,21 * Depreciation: 70,12 * Profit before Tax: 14,52,09 * Provision for Taxation: 3,91,70 * Deferred Tax: (66) * Total amount available for appropriation: 10,61,05 * Less: Transfer to General Reserve: 3,00,00 * Proposed Dividend: 17,02 * Balance brought forward from last year: 7,44,03 * Balance carried forward: 39,65,59 **Auditor's Report Highlights:** * The auditors confirm that the company has maintained proper records of fixed assets, the inventory verification has been carried out at reasonable intervals, and cost records have been maintained. * There were no material discrepancies noticed. * Auditors’ opinion states that the financial statements give a true and fair view of the company’s affairs and that the company has adequate internal financial controls. * Compliance with specified accounting standards has been ensured. * Auditor notes that the annual returns of the company have been placed on the website. * The auditors did not find any fraud on or by the company been noticed or reported during the year. *The Company has transferred to General Reserve thousand Rs.30000 and payment of Dividend, @ Rs.2.00 per equity share subject to approval by the members at the ensuing Annual General Meeting. Total financial outgo will be Rs.17.02 Lakhs. *There has been no change in authorised, issued subscribed and paid up share capital during the year under review. This summary encapsulates the key financial information, operational highlights, and governance-related disclosures from the provided document.

Deys Medical Stores (Mfg) Limited Unlisted Shares

Dey's Medical Stores (Manufacturing) Ltd. provides standalone financial statements for the period of 01/04/2019 to 31/03/2020. The corporate identity number is U24232WB1957PLC023528. The permanent account number of the entity is AABCD1608D. The address of the registered office is 62 Bondel Road, Kolkata, West Bengal, 700019, India. The type of industry is commercial and industrial. The registration date is 01/08/1957. The company is a Public Company Limited by Shares /Indian Non Government Company. The company is not listed. There are 839 employees at the end of the financial year. The company has not published a sustainability report. The date final accounts were approved was 05/11/2020. The period covered by the financial statements is 12 months, reporting from 01/04/2019 to 31/03/2020. The report is standalone. It contains financial statements, in INR thousands, using thousands level of rounding. The cash flow statement type is indirect method. The registrar and transfer agent is Maheswari Datamatics Pvt. Ltd. located at 23 R N Mukherjee Road, Kolkata 700001. The company does not maintain relevant documents in electronic form. There is one product or service category. The principal product is pharmaceutical products. The principal products or services are ITONE EYE DROP with a turnover of 2,07,130 and ENTEROMYCETIN SYRUP with a turnover of 1,20,164. The highest turnover for products is ITONE EYE DROP at 2,07,130 and ENTEROMYCETIN SYRUP at 1,20,164. The unsecured loans are 1,13,062 and total change in indebtness is -1,13,062. The Principal amount at end of financial year is 2,07,70,985 and total indebtedness at end of financial year is 2,07,70,985. The total number of shares held at end of period for Dey's Medical Stores Pvt Ltd is 8,36,491. The percentage of total shares held at end of period is 98.27%. The total number of shares held at end of period for Gautam Dey is 773. The percentage of total shares held at end of period is 0.09%. Dey's Medical Stores PVT LTD is a HOLDING company located at 1B, DEODAR STREET, KOLKATA - 700019, INDIA with CIN U51217WB1949PTC017847 and owns 98.27% of shares. The applicable section is 2(46). Gautam Dey and Ranajit Dey signed the board report on 05/11/2020. Gautam Dey is the Managing Director with DIN 01277238, and Ranajit Dey is the Wholetime Director with DIN 01277323. There was no change in promoters’ shareholding. The shareholding at the beginning of the year (01/04/2019) was 8,36,491 shares for Dey's Medical Stores PVT LTD and 773 shares for Gautam Dey. The percentage of total shares held was 98.27% and 0.09% respectively. The increase/decrease in shareholding during the year was 0 shares for both, with a 0.00% change. At the end of the period (31/03/2020), the total number of shares held was 8,36,491 and 773 shares, and the percentage of total shares held remained at 98.27% and 0.09%. The number of demat shares held at the end of period are 0. The number of physical shares held at end of period are 8,51,186. The total number of shares held at end of period are 8,51,186. Percentage of total shares held at end of period are 100.00%. Percentage of change in shares held during year is 0.00%. For Promoters the number of demat shares held at the end of period is 0. The number of physical shares held at end of period are 8,37,264. The total number of shares held at end of period are 8,37,264. Percentage of total shares held at end of period are 98.36%. Percentage of change in shares held during year is 0.00%. Individual / HUF total number of shares held at end of period is 773 and the percentage of total shares held is 0.09%. The number of demat shares held at end of period are 0. The number of physical shares held end of period are 13,922. The total number of shares held at end of period are 13,922. The percentage of total shares held at end of period is 1.64%. The Percentage of change in shares held during the year is 0.00%. Indian non-corporate bodies physical shares at end of period is 6,091. New India Assurance Co. Ltd. is the top 1 shareholder, Ruma Rudra is the top 2 shareholder, Nirmal Baran Bhattacharjee is the top 3 shareholder, Sandip Rudra is the top 4 shareholder, Dhruba Das is the top 5 shareholder, Subha Sankar Nandi is the top 6 shareholder, Subrata Basu is the top 7 shareholder, Bani Dey is the top 8 shareholder, Bhupati Mohan Sen is the top 9 shareholder and Prakash Chandra Dey is the top 10 shareholder. The name of the main product or service is I TONE EYE DROP Enteromycetin Suspension 60 ml and the second product/service is Enteromycetin Suspension 60 ml. The NIC code for I TONE EYE DROP is 30049001 and for Enteromycetin is 30042001. Percentage to total turnover of company for the eye drop is 19.34% and 11.04% for the suspension. The company's board recommends a transfer of 20000 to General Reserve and recommends payment of dividend @ Re.1 per equity share. The total financial outgo will be Rs. 8.51 lakhs. Revenue from Operations amounted to Rs.10901.09 Lakhs as compared to Rs.10521.23 Lakhs. Company's Profit before Tax is Rs.942.22 Lakhs against Rs.989.68 Lakhs. The Company is now fully Schedule M compliant and has now also become GLP (Good Laboratory Practices) compliant. All operations of the Company were disrupted during the first quarter of the current financial year 2020-21 due to impact of COVID-19. Sourendro Prasad Saha is due to retire by rotation at the ensuing Annual General Meeting, and is recommended for reappointment. Rajarshi Dutta was appointed as Chief Executive Officer of the Company from 16th December 2019 till the closing of business hours of 31st December, 2021 on contractual basis. The Board of Directors duly met five times during the financial year from 1st April, 2019 to 31st March, 2020. The company has formulated and adopted a Risk Management Policy and taken COVID-19 Insurance Policy upto a sum of Rs.1,00,000/- (Rupees One Lakh) for each employee including contractual employees. Contracts and Arrangements now existing with Dey's Medical Stores Private Limited (DMSPL) and Dey's Medical (U.P.) Private Limited [DM(UP)PL] were approved by the board as transactions in ordinary course of business on the same footing as if such transactions were entered with unrelated parties on arm's length basis. Your directors wish to place on record the utmost cooperation and support extended by various departments and agencies of the State & Central Government, UCO Bank, Bandhan Bank, ICICI Bank, Indian Drug Manufacturer's Association (IDMA), Ayurvedic Drug Manufacturer's Association and various Chambers of Commerce, in the various fields of the companies' activities. M/s. Nundy Roy & Co., Chartered Accountants, was appointed as Auditor of the Company for a period of 5 years. Details regarding energy conservation are given in Annexure B and Annual Report on CSR Activities is annexed to this Board's Report and marked as Annexure - C. The CSR Policy is available on the website of the Company at the webaddress - www.deysmedical.com The company implemented conservation of energy which included: continuing upgradation to Heating Ventilation Air-Conditioning and Cooling (HVAC), continuing replacement of old / rewinding motors with energy efficient motors, installation of VFD's in the process equipment's, replacement of partial damaged / old cooling coil of AC pkg unit & Chiller with new one, continuing Cleaning & Maintenance of Boiler with dosing of chemicals in daily / monthly basis, periodic checking of steam lines & its leakage, upgrading and periodic checking of APFC Panels, and contiuning replacement of old 36W/40W tube light fittings with 18W/22W LED fixtures. Improvements include: regularly checking of HVAC systems, replacement of old motors with high energy efficient motors, and the use of VFDs, chemical dosing of chemical and proper cleaning of boiler, and periodic checking of APFC panels. Saving of 10 to 15% of electricity consumption by the implementation of LED fixtures in phase wise. The Company has developed new processes and has efforts for evaluation of single doses safety and efficacy study of LivinaC/B?B= a polyherbal capsule based on OECD guidelines and Assessment of Acute Oral Toxicity Study of TrasinaC/B?B= - an Ayurvadic Herbal Formulation on Experimental Models. The expenditure on R & D :Capital Expenditure is 25.53 and Recurring (including Market Research & Development) is 149.32. Total expenses is 174.85. Percentage of Revenue from Operations 1.60 Foreign Exchange Earnings and Outgo. Foreign Exchange Export Sales (FOB) is NIL. Foreign Exchange Outgo (including raw materials, spare parts, Capital Goods and other Expenditure in foreign currency) is 479.79 A brief outline of the Company's CSR Policy include contribution to Prime Minister National Relief Fund, Eradicating extreme hunger and poverty, Promoting education, Promoting Healthcare, Social Business Projects and Ensuring Environmental Sustainability. Average net profit of the company for last three financial years is Rs.7,37,18,667/- and prescribed CSR Expenditure is Rs.14,74,373/-. Total amount to be spent for the financial year is Rs.14,74,373. The amount unspent, if any, is NIL.

Deys Medical Stores (Mfg) Limited Unlisted Shares

Dey's Medical Stores (Manufacturing) LTD. Financial Report Summary: **General Information:** * The document presents the standalone financial statements of Dey's Medical Stores (Manufacturing) LTD for the period April 1, 2018, to March 31, 2019, with comparative figures from April 1, 2017, to March 31, 2018. * The company's corporate identity number is U24232WB1957PLC023528, and its permanent account number is AABCD1608D. * The registered office is located at 62, Bondel Road, Kolkata - 700 019. * The company is a commercial and industrial type of industry and classified as an unlisted public company. * The board approved the final accounts on August 9, 2019. **Principal Products and Services:** * The company's principal product category is pharmaceuticals. * The highest turnover was generated by "ITONE EYE DROP" and Enteromycetin syrup with turnover 2,13,464 and 1,14,799 respectively. **Directors and Shareholding:** * Gautam Dey (DIN 01277238) and Ranajit Dey (DIN 01277323) are the directors signing the board report. * The promoters, including Dey's Medical Stores Pvt. Ltd. and Gautam Dey, held the majority of shares. * Dey's Medical Stores PVT. LTD. holds 8,36,491 shares which is 98.27%. * Shares of New India Assurance Co. Ltd. is 7823 number of shares which is 0.92%. * Shareholding of key managerial personnel and directors are also detailed. **Financial Performance:** * Revenue from Operations increased from Rs. 98,32,43 Thousands to Rs. 105,21,23 Thousands. * Profit before Tax increased from Rs. 356,83 Thousands to Rs. 989,68 Thousands. * Net profit for the year is Rs. 68,613 Thousands * The directors recommend a dividend of Rs. 1.50 per equity share. * Total financial outgo will be Rs.15.39 lakhs, including dividend distribution tax of Rs.2.62 lakhs. **Key Financial Data (in Thousands of INR):** * Share capital: 8,512 * Reserves and surplus: 5,25,950 * Long-term borrowings: 15,723 * Short-term borrowings: 5,161 * Trade payables: 62,782 * Total assets: 7,26,343 * Unsecured loans : 20,884.04 * Net change increase (decrease) : 5,464.45 * The Company's turnover of ITONE EYE DROP is 20.32% and Enteromycetin Suspension 60 ml. is 10.93% **Key Financial Ratios:** * The shareholding of promoters: 98.27% * The percentage demat shares held at end of period: 98.45% * The financial performance of key products and services are also included. **Other Disclosures:** * The report discusses energy conservation measures, technology absorption, and foreign exchange earnings and outgo. * Key initiatives include replacing old motors with high-efficiency ones, using direct couplings, and implementing LED lighting. * Describes research and development efforts, including new processes developed and product improvements. * Directors' Responsibility Statement confirms adherence to accounting standards, maintenance of records, and a going concern basis. * Details changes in directors and key managerial personnel. * M/s. Nundy Roy & Co. have been appointed as the statutory auditor of the company. * The company has transferred Rs.8,403/- to the IEPF and credited to the Demat Account of IEPF. * Discusses internal financial controls, risk management, and corporate social responsibility (CSR) activities. * The Company's CSR Policy includes several initiatives such as contribution to Prime Minister's National Relief Fund, promoting education, and ensuring environmental sustainability. Expenditure 12,04,980/- * Details of remuneration to directors and key managerial personnel. * Details of penalties, punishment, and compounding of offenses are NIL. * The Company is also GLP (Good Laboratory Practices) compliant * Contracts and Arrangements with Related Parties. * The Board has not approved Contracts and Arrangements with Related Parties within the meaning of Section 2 (76) of the Companies Act 2013 This summary provides a detailed overview of the standalone financial statements of Dey's Medical Stores (Manufacturing) LTD for the specified period, capturing all the key information and disclosures presented in the document.